Global Lung Cancer Academy
Sharing Best Practices to Optimize Patient Care in Europe
Overview
In recent years, progress in screening of high-risk populations, identification of actionable molecular targets, and immunotherapy have rapidly transformed the treatment paradigm for patients with lung cancer. Aptitude Health developed the Global Lung Cancer Academy to help physicians bridge the gap between innovation and implementation for patient care.
Date and Location
November 7 and 14, 2022, Virtual Meeting
Chair
Corey J. Langer, MD, FACP
University of Pennsylvania Perelman School of Medicine, USA
Solange Peters, MD, PhD
University Hospital of Lausanne, Switzerland
Faculty
Benjamin Besse, MD, PhD
Institute Gustave Roussy, Villejuif, France
Federico Cappuzzo, MD, PhD
AUSL della Romagna, Ravenna, Italy
Anne-Marie C. Dingemans, MD, PhD
Erasmus University Medical Center, Rotterdam, the Netherlands
Umberto Malapelle, PhD
University of Naples Federico II, Italy
Luis Paz-Ares, MD, PhD
Hospital Universitario 12 de Octubre, Madrid, Spain
Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain
Johan Vansteenkiste, MD, PhD
Catholic University of Leuven, Belgium
Antonio Passaro, MD, PhD
European Institute of Oncology, Milan, Italy
|
Agenda |
This 2-day interactive virtual meeting with global experts will focus on the management of patients with lung cancer in Europe. DAY 1: Follow presentations on the optimal management of early-stage NSCLC, join a debate on neoadjuvant vs adjuvant therapy, and engage with the faculty in panel discussions DAY 2: Learn about treatment strategies for patients with metastatic NSCLC and attend patient case-based panel discussion exemplifying these strategies |
Day1: Plenary Sessions
Monday, November 7, 2022 from 15.00 – 19.00 CET (Central European Time)
| Time (CET) | Topic | Presenter |
| 15.00 – 15.10 | Welcome and Meeting Overview | Solange Peters |
| 15.10 – 15.40 | Recent Developments in NSCLC – What Is New in Research and Management? • Overview of recently presented data in NSCLC |
Corey Langer |
| 15.40 – 16.00 | Biomarker and Mutational Testing for NSCLC – What, Where, and When? • NSCLC heterogeneity, overview of current and emerging biomarkers and co-mutations, and best practices and guidelines for testing at diagnosis and during treatment of NSCLC |
Umberto Malapelle |
| 16.00 – 16.20 | Targeted Therapies for Early-Stage NSCLC – Evidence-Based Data and Perspectives • Summary of targeted therapies for different NSCLC genotypes |
Enriqueta Felip |
| 16.20 – 16.40 | Adjuvant Therapy in Resectable NSCLC • Current standard practices and ongoing studies |
Benjamin Besse |
| 16.40 – 17.10 | Tumor Board Discussion • Local case 1: Resectable NSCLC • Local case 2: Unresectable NSCLC • Discussion and Q&A |
Moderator: Solange Peters Johan Vansteenkiste Daphne Dumoulin All faculty |
| 17.10 – 17.20 | Break | |
| 17.20 – 17.40 | Neoadjuvant Therapy for NSCLC – Is It Ready for Prime Time? • Current state of neoadjuvant therapy in resectable NSCLC |
Anne-Marie Dingemans |
| 17.40 – 18.00 | Locally Advanced Unresectable NSCLC – What Are the Options? • Current standard practices and ongoing studies |
Antonio Passaro |
| 18.00 – 18.30 | Debate: Adjuvant or Neoadjuvant Therapy for NSCLC? • Neoadjuvant therapy • Adjuvant therapy • Discussion and voting |
Moderator: Corey Langer Johan Vansteenkiste Benjamin Besse All faculty |
| 18.30 – 18.50 | Options After Early-Stage Relapse • Work-up first recurrence vs de novo oligometastatic NSCLC including sites of involvement (isolated vs systemic recurrence) |
Federico Cappuzzo |
| 18.50 – 19.00 | Session Close | Corey Langer |
Day 2: Plenary Sessions
Monday, 14 November 2022 from 16.00 – 19.15 CET (Central European Time)
| Time (CET) | Topic | Presenter |
| 16.00 – 16.10 | Session Open | Corey Langer |
| 16.10 – 16.30 | Optimizing First-Line Therapy in NSCLC – Integration of Immunotherapy Into Frontline Regimens • Optimal use of immunotherapeutic treatment choices in frontline NSCLC |
Luis Paz-Ares |
| 16.30 – 16.50 | Current Immunotherapy Options for Relapsed NSCLC • Optimal use of immunotherapeutic treatment choices in relapsed NSCLC including considerations for potential rechallenge, and treatment selection mono vs combination therapy |
Benjamin Besse |
| 16.50 – 17.25 | Tumor Board Discussion • Local case 1: 1L chemo-IO in NSCLC • Local case 2: ALK+ NSCLC • Discussion and Q&A |
Moderator: Solange Peters Francesca Fusco Luis Angel Leon Mateos All faculty |
| 17.25 – 17.35 | Break | |
| 17.35 – 17.50 | ALK Inhibitors in NSCLC • Considerations for optimal use in clinical practice in patients with and without brain metastasis |
Enriqueta Felip |
| 17.50 – 18.05 | EGFR Inhibitors in NSCLC • Considerations for optimal use in clinical practice |
Johan Vansteenkiste |
| 18.05 – 18.30 | Other Targets in NSCLC • Considerations for optimal use of ROS1, NTRK, RET and MET inhibitors in clinical practice |
Anne-Marie Dingemans |
| 18.30 – 19.05 | Tumor Board Discussion • Local case 1: ALK+ NSCLC • Local case 2: EGFR+ NSCLC • Discussion and Q&A |
Moderator: Corey Langer May-Lucie Meyer Xander Verbeke All faculty |
| 19.05 – 19.15 | Session Close | Solange Peters |
